Disclosed herein is a stable amorphous co -precipitate of (-)-(S)-5-hydroxy-2-[N-n- propyl-N-2-(2-thienyl)ethylamino]tetralin (Rotigotine) with pharmaceutically acceptable excipients, methods for the preparation, pharmaceutical compositions, and methods of treating thereof. Advantageously, the amorphous co-precipitates of rotigotine have improved physio chemical characteristics that assist in their effective bioavailability.
